-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: mergers
BIO-Europe Spring Opening Remarks
BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >
Five things you need to know about the state of the industry
What is the state of the biotechnology industry? To find out where the it stands and what strategies you need to survive, read Ernst & Young’s 25th annual industry report, Beyond borders: global biotechnology report 2011, that was released during a super session at the 2011 BIO International Convention. What were the industry’s profits last year? What kind of companies received funding? How should you engage the regulators? What new competencies do you need to Read More >
Beware the Liability Gaps in Biotechnology M&As
Mike Yeager, Senior Underwriting Specialist, Chubb Mergers and acquisitions continue to be a source of growth for the biotechnology industry. Even the financial crisis has not significantly slowed this trend. In fact, a weakened global economy may have further fueled consolidation as biotechnology companies sought additional efficiencies in R&D, procurement or administration. Since many biotechnology companies have complex corporate structures—some with hundreds of subsidiaries—executives at acquiring companies recognize that along with the benefits of the Read More >
